Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa

Published:2022-04-19 Issue:4 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Poirel Laurent¹²³^ORCID,Ortiz de la Rosa Jose-Manuel¹,Sadek Mustafa¹⁴^ORCID,Nordmann Patrice¹²³⁵^ORCID

Affiliation:

1. Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

2. INSERM European Unit (IAME), University of Fribourg, Fribourg, Switzerland

3. Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland

4. Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt

5. Institute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland

Abstract

The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam (AZA), and cefiderocol (FDC) was evaluated both in Pseudomonas aeruginosa and in Escherichia coli using isogenic backgrounds. Although metallo-β-lactamases conferred resistance in most cases, except for AZA, several clavulanic-acid-inhibited extended-spectrum β-lactamases (PER, BEL, SHV) had a significant impact on the susceptibility to CZA, C/T, and FDC.

Funder

University of Fribourg

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00039-22

Reference13 articles.

1. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

2. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

3. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens